ARTICLE | Strategy
Road to acquisition
How Belgian biotech Ablynx fits Sanofi’s R&D strategy
February 3, 2018 2:09 AM UTC
Sanofi’s proposed acquisition of Ablynx N.V. puts considerable value not only on the Belgian biotech’s lead hematology asset caplacizumab, but also on its Nanobody platform, which fits the pharma’s R&D strategy of prioritizing development of multispecific modalities across its areas of therapeutic focus.
The French pharma, which had been test driving the platform under a July 2017 deal, also could be in a position to more broadly exploit the platform than Ablynx could have done as a stand-alone company...